A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer
Authors
Keywords
Breast cancer, immunotherapy, cancer vaccine, cytotoxic T-cell lymphocyte response, peptide, poly-ICLC, TLR3, agonist
Journal
Journal for ImmunoTherapy of Cancer
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-11-07
DOI
10.1186/s40425-017-0295-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
- (2016) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
- (2016) K. J. McCann et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
- (2016) Nadia M. Luheshi et al. Oncotarget
- Designing vaccines to prevent breast cancer recurrence or invasive disease
- (2015) Sasha E Stanton et al. Immunotherapy
- Role of the Tumor Microenvironment in Breast Cancer
- (2015) Savas D. Soysal et al. PATHOBIOLOGY
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas
- (2014) Ivana Mrklić et al. ACTA HISTOCHEMICA
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
- (2014) S A Joosse et al. BRITISH JOURNAL OF CANCER
- Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
- (2014) H. Okada et al. CLINICAL CANCER RESEARCH
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
- (2014) Aaron P. Rapoport et al. CLINICAL CANCER RESEARCH
- The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
- (2014) Erika J Schneble et al. Immunotherapy
- Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination
- (2014) Yared Hailemichael et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Melanoma-associated antigen genes: a new trend to predict the prognosis of breast cancer patients
- (2014) Eman Abd-Elkader Abd-Elsalam et al. MEDICAL ONCOLOGY
- Direct T Cell Activation via CD40 Ligand Generates High Avidity CD8+ T Cells Capable of Breaking Immunological Tolerance for the Control of Tumors
- (2014) Ruey-Shyang Soong et al. PLoS One
- Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide
- (2013) Elise P. Salerno et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease
- (2013) M. L. Disis et al. Cancer Prevention Research
- Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors
- (2013) Lisa L.R. Hartman et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
- (2013) Claudia Marcela Diaz-Montero et al. Journal of Translational Medicine
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
- (2013) Yared Hailemichael et al. NATURE MEDICINE
- Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
- (2013) T. Tsuji et al. Cancer Immunology Research
- Peptide-based anticancer vaccines
- (2013) Yared Hailemichael et al. OncoImmunology
- A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
- (2013) Daniel M Geynisman et al. Journal for ImmunoTherapy of Cancer
- Expression of cell adhesion molecules and prognosis in breast cancer
- (2012) S. Saadatmand et al. BRITISH JOURNAL OF SURGERY
- Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
- (2012) P. Sabbatini et al. CLINICAL CANCER RESEARCH
- Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced With Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC)
- (2012) Baldev Vasir et al. JOURNAL OF IMMUNOTHERAPY
- Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells
- (2012) Laura P. Schneider et al. VACCINE
- Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients
- (2011) Elizabeth A. Mittendorf et al. CANCER
- Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
- (2011) Sylvia Adams et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Vaccine-site Microenvironment Induced by Injection of Incomplete Freundʼs Adjuvant, With or Without Melanoma Peptides
- (2011) Rebecca C. Harris et al. JOURNAL OF IMMUNOTHERAPY
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
- (2011) Gary K. Koski et al. JOURNAL OF IMMUNOTHERAPY
- Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites
- (2010) A. Soeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freundʼs Adjuvant for Multipeptide Melanoma Vaccines
- (2010) Craig L. Slingluff et al. JOURNAL OF IMMUNOTHERAPY
- A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma
- (2010) M. R. Rosenfeld et al. NEURO-ONCOLOGY
- Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C)
- (2010) Darin A. Wick et al. VACCINE
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
- (2009) C. L. Slingluff et al. CLINICAL CANCER RESEARCH
- Topical resiquimod promotes priming of CTL to parenteral antigens
- (2009) Brent A. Chang et al. VACCINE
- Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence
- (2008) Jarrod P. Holmes et al. CANCER
- The E75 HER2/neu peptide vaccine
- (2008) Elizabeth A. Mittendorf et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2008) G. E. Peoples et al. CLINICAL CANCER RESEARCH
- A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer
- (2008) Kimberly A. Chianese-Bullock et al. JOURNAL OF IMMUNOTHERAPY
- A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
- (2008) Nicholas Butowski et al. JOURNAL OF NEURO-ONCOLOGY
- A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
- (2008) Nicholas Butowski et al. JOURNAL OF NEURO-ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started